



Veracyte, Inc.  
Investor Relations Department  
6000 Shoreline Court  
Suite 300  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: VCYT

Last Trade:	6.49
Trade Time:	9:58 AM ET Dec 11, 2017
Change:	0.03  (+0.464%)
Day Range	6.46 - 6.61
52-Week Range	5.75 - 9.80
Volume	12,295

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 28, 2017*  
[Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis](#)
- Nov 15, 2017*  
[Veracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference](#)
- Nov 9, 2017*  
[Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology](#)
- Nov 6, 2017*  
[Veracyte Announces Third Quarter 2017 Financial Results](#)
- Nov 3, 2017*  
[CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 31, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)